Eli Lilly's mirikizumab shows promise in Phase III Crohn's disease trial
Mirikizumab demonstrated significant improvements in Crohn's disease patients.
Source: yahoo.com
Mark Genovese News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Genovese. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Genovese Today - Breaking & Trending Today
Lilly Reports Positive Phase 3 Trial Results Of Mirikizumab In Crohn's Disease
Drug major Eli Lilly and Co. (LLY) announced Tuesday that its pivotal Phase 3 VIVID-1 study of mirikizumab in Crohn's disease showed that more than one-half of patients achieved clinical remission at one year, including patients with previous biologic failure.
Source: rttnews.com
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin...
Source: prnewswire.com
Eli Lilly: conclusive trial for lebrikizumab in eczema -March 11, 2024 at 07:15 am EDT
Eli Lilly has presented the results of a Phase III study of lebrikizumab as a treatment for eczema in non-white people. In this study, the treatment showed an improvement in skin clearance and relief...
Source: marketscreener.com
Eli Lilly (LLY) Q3 2023 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2023.
Source: fool.com